<DOC>
	<DOCNO>NCT01470326</DOCNO>
	<brief_summary>In survey , collect safety efficacy information Bazedoxifene daily medical practice examine . In addition , necessity special Investigation post-marketing clinical study examine , investigate unexpected adverse drug reaction survey period understand status frequency adverse drug reaction daily medical practice .</brief_summary>
	<brief_title>Viviant 20mg Special Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All subject investigator prescribes first Bazedoxifene ( Viviant ) Tablets register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Post menopausal woman subject Osteoporosis experience use Bazedoxifene . Subject present past venous thromboembolism deep venous thrombosis , pulmonary embolism , retinal venous thrombosis Subject longterm immovability ( postoperative recovery , longterm bed rest ) Subject antiphospholipid antibody syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Post menopausal woman</keyword>
	<keyword>SERM</keyword>
	<keyword>Japanese</keyword>
	<keyword>Viviant</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
	<keyword>Long term treatment</keyword>
</DOC>